Patients (153) with biopsy-proven primary systemic amyloidosis (AL) were evaluated for their response rate to alkylating agent-based chemotherapy. Twenty-seven of the patients (18%) responded.

Because the blood–brain barrier may pose a particular challenge for the delivery of large, protein-based therapies, Amyl’s focus is currently on systemic amyloidosis diseases. Amyl ...

The challenge in this case was the determination of primary amyloidosis. Virtually all patients with AL amyloidosis have elevations of the responsible FLC. In this patient, the initial concern was ...

Cohen AD, Comenzo RL . Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program 2010; 2010: 287–294.